Results 101 to 110 of about 394,701 (235)

Ocular Tuberculosis Initially Presenting as Central Retinal Vein Occlusion

Case Reports in Ophthalmology, 2010
A 23-year-old man presented with central retinal vein occlusion. The retinal haemorrhages worsened and signs of retinal vasculitis appeared later as vision dropped from 6/60 to Counting Fingers. No signs of systemic disease were observed. Routine Mantoux
Muiz Mahyudin, May May Choo, Norlina Mohd Ramli, Sharifah S. Omar   +3 more
doaj   +1 more source

GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane‐induced lupus mouse model

British Journal of Pharmacology, Volume 182, Issue 16, Page 3786-3799, August 2025.
Background and Purpose Systemic lupus erythematosus is an autoimmune, multisystemic disease affecting all organs in the body. Accrued evidence has elucidated a role for autophagy in the onset and severity of systemic lupus erythematosus. The antimalarial drug hydroxychloroquine constitutes the cornerstone of standard of care for systemic lupus ...
Eya Toumi, Eloïne Bestion, Muriel Militello, Hubert Lepidi, Anne Plauzolles, Nathalie Bardin, Daniel Bertin, Laurent Chiche, Jean‐Louis Mege, Philippe Halfon, Soraya Mezouar   +10 more
wiley   +1 more source

Arteritic Anterior Ischemic Optic Neuropathy Treated with Intravenous Prostaglandin E1 and Steroids. [PDF]

, 2010
Arteritic anterior ischemic optic neuropathy (AAION) is an acute ischemia of the posterior ciliary arteries and/or ophthalmic artery due to inflammation.
A. Pascarella, G. Belcaro, M. De Angelis, M. R. Cesarone, NEBBIOSO, Marcella, R. D. Steigerwalt, R. Gattegna   +6 more
core   +1 more source

Proteomic Profiling of the Large‐Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling

Arthritis &Rheumatology, Volume 77, Issue 7, Page 884-900, July 2025.
Objective Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large‐vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid in developing better biomarkers and treatments. Methods Plasma proteomic profiling of 184 proteins was performed in two cohorts. Cohort 1 included
Robert T. Maughan, Erin Macdonald‐Dunlop, Lubna Haroon‐Rashid, Louise Sorensen, Natalie Chaddock, Shauna Masters, Andrew Porter, Marta Peverelli, Charis Pericleous, Andrew Hutchings, James Robinson, Taryn Youngstein, Raashid A. Luqmani, Justin C. Mason, Ann W. Morgan, James E. Peters   +15 more
wiley   +1 more source

Intravitreal triamcinolone for cancer-associated retinopathy refractory to systemic therapy [PDF]

, 2012
Purpose: The purpose of this study is to report the use of intravitreal triamcinolone for treatment of cancer-associated retinopathy (CAR) refractory to systemic therapy. Methods: This was a retrospective chart review study.
Huynh, Nancy, Lobo, Ann-Marie, Shildkrot, Yevgeniy, Sobrin, Lucia   +3 more
core   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

A cross-sectional study of submacular thickening in intermediate uveitis and determination of treatment threshold. [PDF]

, 2016
The aim of this work is to refine understanding of anatomical and functional alterations in eyes with Intermediate Uveitis (IU), their natural history in mild cases not necessitating treatment and their response to treatment in severely affected eyes ...
Balaskas, K., Guex-Crosier, Y., Simonazzi, B.   +2 more
core   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Blau Syndrome (Juvenile Systemic Granulomatosis): State‐Of‐The‐Art Review

Pediatric Dermatology, Volume 42, Issue 4, Page 728-734, July/August 2025.
ABSTRACT Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain‐of‐function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated.
Ou Jia (Emilie) Wang, Marianna Jacob, Richard I. Crawford, Joseph M. Lam   +3 more
wiley   +1 more source

Atheroembolic renal disease [PDF]

, 2010
Atheroembolic renal disease develops when atheromatous aortic plaques rupture, releasing cholesterol crystals into the small renal arteries. Embolisation often affects other organs, such as the skin, gastrointestinal system, and brain.
Ravani P., Scolari F
core   +1 more source